$8.789
+1.051 (+11.96%)終値時点
- 高値
- 9.140
- 始値
- 7.850
- 出来高加重平均価格
- 8.54
- 出来高
- 44.87K
- 時価総額
- —
- 安値
- 7.683
- 売買代金
- 383.06K
- EV/EBITDA(TTM)
- -2.20
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
AI分析 of Picard Medical Inc (PMI)
買いPicard Medical Inc (PMI) appears to be a good buy right now due to its recent revenue growth of 39% in Q2 2026, reaching approximately $3.0 million, and a notable improvement in gross margin to 20.9%. However, the main risk is the ongoing net loss of approximately $5.7 million for the same quarter, which indicates that while the company is improving, it still faces significant financial challenges.
バリュエーション指標
イベントタイムライン
ニュース
7.009-10NewsfilterInvestigation into Picard Medical Executives for Breach of Fiduciary Duties
9.508-24NASDAQ.COMPicard Medical Reports Strong Q2 Results, Shares Surge 40%
8.507-27GlobenewswirePicard Medical Unveils Next-Gen Artificial Heart System
8.507-27NewsfilterPicard Medical Unveils Emperor Drive System at IEEE EMBC 2026
8.507-27seekingalphaPicard Medical Secures Compliance Period Until 2027 from NYSE American
PMI のよくある質問 — Alphio AI が回答
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber. It operates in the Healthcare sector.
Picard Medical Inc (PMI) appears to be a good buy right now due to its recent revenue growth of 39% in Q2 2026, reaching approximately $3.0 million, and a notable improvement in gross margin to 20.9%. However, the main risk is the ongoing net loss of approximately $5.7 million for the same quarter, which indicates that while the company is improving, it still faces significant financial challenges.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。